RESEARCH
CLINICAL / EPIDEMIOLOGICAL RESEARCH
Blood Pressure
Systolic Blood Pressure Intervention Trial (SPRINT)
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
Principal Investigator
Paul Drawz, MD
Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu
Diabetes Kidney Disease
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Transplantation Research (Kidney and Pancreas)
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Principal Investigator
Samy Riad, MD, MS
Co-Investigator
Richard Spong, MD
Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu
Phase 3
A Randomized, Controlled, Multi-Center, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus and Mycophenolate-Based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
Principal Investigator
Erik Finger, MD, PhD
Co-Investigator
Samy Riad, MD, MS
Study Coordinator
Marcia Brott
brott001@umn.edu
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Principal Investigator
Samy Riad, MD, MS
Study Coordinator
Ghislaine Feussom, MPH
feuss001@umn.edu
Cf-DNA Assay During Treatment of Acute Rejection-Pilot Study
Principal Investigator
Arthur Matas, MD
Co-Investigators
Samy Riad, MD, MS
Study Coordinators
Marcia Brott
brott001@umn.edu
Alyssa Nelson, BS
nels9147@umn.edu
Phase 1 and Phase 2 Trial
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Principal Investigator
Michelle Rheault, MD
Co-Investigator
Samy Riad, MD, MS
Study Coordinators
Marcia Brott
brott001@umn.edu
Thu Danh, MPH, CRRP
danhx005@umn.edu
Use of dd-cfDNA in Multi-Organ Transplant Rejection Detection (MOTR)
Principal Investigator
Samy Riad, MD, MS
Co-Investigator
Raja Kandaswamy, MD
Study Coordinators
Alyssa Nelson, BS
nels9147@umn.edu
Marcia Brott
brott001@umn.edu
Glomerular Diseases & Vasculitis Research
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
IGA NEPHROPATHY
Phase 3 Trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Principal Investigator
Surabhi Thakar, MD
Co-Investigator
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Joy Bolea, RN, MS
jbolea@umn.edu
MEMBRANOUS NEPHROPATHY
Phase 2 Trial
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Patrick Nachman, MD
Study Coordinators
Joy Bolea, RN, MS
jbolea@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
NEPHROTIC SYNDROME
The Nephrotic Syndrome Study Network (NEPTUNE)
Principal Investigator
Patrick Nachman, MD
Co-Principal Investigator
Michelle Rheault, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Scott Rajala, CCRP
srajala@umn.edu
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase 3 Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Principal Investigator
Surabhi Thakar, MD
Co-Investigators
Patrick Nachman, MD
Katti Woerner, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Programs
MINNESOTA GLOMERULAR DISEASE PROGRAM
To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials. Learn More
MINNESOTA MULTIDISCIPLINARY VASCULITIS PROGRAM
To provide patients with glomerular disease with expert, individualized care and access to clinical trials. Learn More
StudyFinder is a University of Minnesota website that displays a searchable listing of studies, which are extracted from ClinicalTrials.gov. At StudyFinder you can explore University health studies currently seeking participants.
Clinicaltrials.gov is a database of privately and publicly funded clinical studies conducted around the world.